Notes - Consolidated Statement Of Comprehensive Income

HISAMITSU PHARMACEUTICAL CO.,INC. - Filing #7607422

Concept 2021-03-01 to
2022-02-28
2021-03-01 to
2022-02-28
Notes - Consolidated statement of comprehensive income
Notes - Consolidated single statement of comprehensive income
Major components of selling, general and administrative expenses
Research and development expenses included in general and administrative expenses and manufacturing costs for period

※2 (前連結会計年度)

一般管理費に含まれる研究開発費は10,766百万円です。

なお、製造費用に含まれる研究開発費はありません。

(当連結会計年度)

一般管理費に含まれる研究開発費は10,613百万円です。

なお、製造費用に含まれる研究開発費はありません。

Notes regarding reclassification adjustments and tax effects relating to other comprehensive income

Talk to a Data Expert

Have a question? We'll get back to you promptly.